InvivoSciences Selected as MassChallenge Finalist

InvivoSciences has been selected as one of the finalist among thousands of global entries to participate in MassChallenge Boston’s 2020 Accelerator. Learn more about MassChallenge Boston’s 2020 program and see the rest of the cohort here. About MassChallenge MassChallenge is a global network of zero-equity startup accelerators. Headquartered in the United States with locations in…
Read more

Global Health and Pharma Award

Invivosciences, Inc has been honored with Global Health and Pharma’s 2020 Biotechnology Award for Best Tissue-Based Assay R&D Engineering Company. We would like to graciously accept this award. And thank GHP for their selection.


Invivosciences, Inc. is honored to work with COVID-19 Task Force to be part of solutions. We are dedicated to innovate and support researchers, medical teams and drug developers world-wide by providing uninterrupted contract research services. Learn more about the COVID-19 Task Force here.

Bio 2020

InvivoSciences has been given the honor to attend and present at the Bio 2020 Annual Meeting in San Diego, California from June 8-11, 2020. InvivoSciences is selected to participate under NIH Innovation Zone and will deliver a company presentation.  Learn more about BIO Digital here.

Brava Magazine Feature

InvivoSciences was recently featured in the February 2020 issue of Brava Magazine. You can read the article below. Previous Next

Welcome New Business Adviser Member, Dr. Lenka Fedorkova

Dr. Lenka Fedorkova InvivoSciences, Inc. is delighted to announce the joining of Dr. Fedorkova to the business team as Strategic Adviser. She is currently CEO/ Founder of bioPrime, LLC, Director Corporate Development at AfaSci Research Laboratories, Inc., and Board Member for Yale Entrepreneurial Institute. She was formerly Executive Manager of SBIR/STTR Programs at the National…
Read more

Join us at Washington DC

Our collaboration with Nihon Kohden and Tokyo Women’s Medical University is presented.

CEO will give a TEDx talk

Stay tuned for more information about this event on October 13th!    

Presenting Monogenic Heart Failure Disease Modeling in Kyoto On September 7th, CSO speaks about monogenic disease modeling using NuHeart™ technology during TERM for heart, blood vessel & lung session. 99-O-5: Personalized micro-3D human heart  tissues for orphan drug development Tetsuro Wakatsuki,Neil Daily,Pinar Kemanli, Michael Greenberg,Jennifer Strande InvivoSciences, Inc. Madison Wisconsin, USA, Washington University, St. Louis, Medical College of Wisconsin.